🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

135 results for “formulation” Clear

  1. Original formulation EMB-001

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule completed

    1 trial

  2. PEG-IFN alfa-2a BA-free formulation (Test)

    Hoffmann-La Roche

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  3. SIBP-A13 formulation for injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  4. Sinovac PCV24 formulation 1

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 1 mab completed

    2 trials

  5. Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

  6. TAK-385 T2 Formulation

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  7. Tamsulosin formulation-A

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy

    phase 1 small molecule completed

    1 trial

  8. To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents after single dose administration and to assess BE of a regular strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents at steady state in men with prostate cancer

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 1 other active

    1 trial

  9. new formulations of 611

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Atopic Dermatitis

    phase 1 small molecule active

    1 trial

  10. telaprevir formulation A

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

  11. Erythromycin 4% topical gel formulation

    BRIGHT MINDS BIOSCIENCES INC.

    Acne Vulgaris

    approved small molecule active

    1 trial

  12. Placebo suspension is identical to Symbioflor®2 liquid formulation in appearance, weight and composition, with the exception that the active ingredient will be omitted. Placebo constitutes are sodium chloride, magnesium sulphate 7H2O, potassium chloride, calcium chloride 2H2O, magnesium chloride 6H2O, and purified water, Symbioflor 2 Tropfen zum Einnehmen, Suspension

    Alphapharm Pty Ltd

    Irritable Bowel Syndrome

    approved small molecule active

    1 trial

  13. Realgar-Indigo Naturalis Formulation Combined with Anlotinib

    The First People's Hospital of Lianyungang

    Platinum-resistant Ovarian Cancer (PROC)

    approved small molecule active

    1 trial

  14. Erythromycin 4% topical gel formulation:

    BRIGHT MINDS BIOSCIENCES INC.

    Inflammation; Skin

    small molecule completed

    1 trial

  15. Innovative Dietary Formulation (Patent ID: CN110250417A)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hypertension

    other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources